Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SHR-1819 injection in seasonal allergic rhinitis
CTR20262507Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1819 in seasonal allergic rhinitis (SAR), sponsored by Hengrui Therapeutics. Started Aug 2026; status: active.
02
Drugs
SHR-1819
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20262507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262507.